There is one clinical trial.
About 5% of COVID-19 patients may present symptoms related to acute ischemic stroke (AIS). Treatment-management and outcomes related to mechanical thrombectomy (MT) for COVID-19 infected patients harboring large vessel occlusion is largely unknown. This multicentric study aims to investigate morbidity, mortality and neurological outcomes after MT performed in patients with COVID-19 infection.
Description: Intrahospital mortality after MT for COVID-19 infected patients harboring large vessel occlusionMeasure: Intrahospital mortality Time: 1day
Description: short-term morbidity after MT for COVID-19 infected patients harboring large vessel occlusionMeasure: short-term morbidity Time: 1 day
Description: Angiographic success after MT for COVID-19 infected patients harboring large vessel occlusionMeasure: Angiographic success Time: 1 day
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports